Volasertib

DB12062InvestigationalSmall molecule

Volasertib has been used in trials studying the treatment of Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Monocytic, Acute, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK1
Curator reviewed
Formula / weight: C₃₄H₅₀N₈O₃ · 618.8126 g/mol (avg)
Code names: BI-6727

Resolves to

Compound

UNII6EM57086EACAS755038-65-4ChEMBLCHEMBL1233528PubChem10461508

Structure

InChIKeySXNJFOWDRLKDSF-STROYTFGSA-NSMILESCC[C@H]1N(C(C)C)C2=NC(NC3=CC=C(C=C3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)=NC=C2N(C)C1=O

Targets

P53350PLK1

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Volasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account